Sign In
Buy ALLK
$0.329
+0 (+0%)
At Close: Aug 14, 2025
LOS ANGELES, CA / ACCESSWIRE / January 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. (
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
01:11pm, Wednesday, 17'th Jan 2024
Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.
Why Is Allakos (ALLK) Stock Down 57% Today?
11:36am, Tuesday, 16'th Jan 2024
Allakos (NASDAQ: ALLK ) stock is taking a beating on Tuesday after the clinical stage biopharmaceutical company revealed results from its latest study. The bad news here comes from the company's Phase
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
11:26am, Tuesday, 16'th Jan 2024
Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.
Allakos to stop further development of skin disease drug, plans job cuts
07:30am, Tuesday, 16'th Jan 2024
Allakos Inc said on Tuesday that it plans to discontinue the development of its experimental skin disease drug after it failed two mid-stage studies.
Why Shares of Allakos Are Up Wednesday
12:10pm, Wednesday, 27'th Sep 2023
An analyst's recommendation may have helped boost Allakos stock. Allakos has two lead therapies to treat autoimmune skin disorders.
Scratching The Surface: Allakos' Novel Take On Urticaria
02:07am, Monday, 18'th Sep 2023
Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirentelimab's Phase 2a data is promising, particularly for
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
09:23am, Sunday, 21'st May 2023
Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%,
Why Allakos Stock Skyrocketed Nearly 9% Higher Today
05:00pm, Friday, 12'th May 2023
An analyst bumped his recommendation higher. This closely followed an encouraging quarterly earnings report/business update from the biotech.
Why Allakos Stock Was Heating Up Today
04:05pm, Tuesday, 07'th Mar 2023
Allakos is barreling toward two mid-stage data readouts that could alter its long-term outlook. An analyst thinks these twin catalysts could cause the biotech's shares to more than quadruple in value.
Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade
01:33pm, Friday, 09'th Dec 2022
Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allakos: Potential For Comeback With Lirentelimab With 2 Indications
03:22am, Tuesday, 18'th Oct 2022
Results from the phase 2b study, using lirentelimab for the treatment of patients with chronic spontaneous urticaria, are expected in the 2nd half of 2023. Xolair naive CSU cohort of 13 patients start
Alkermes, Allakos See Activist Action
06:35pm, Friday, 14'th Oct 2022
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
3 Healthcare Stocks to Sell Before They Die
11:48am, Friday, 30'th Sep 2022
The Fed's key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive.
Why Is Allakos (ALLK) Stock Soaring 25% Today?
12:56pm, Monday, 19'th Sep 2022
On Monday, biotechnology firm Allakos (NASDAQ: ALLK ) announced a public offering that raised gross proceeds of approximately $150 million, sending ALLK stock soaring 25% in the morning session before
